Herpes simplex encephalitis in adults and older children

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

• Herpes simplex encephalitis (HSE) is a neurologically devastating illness associated with substantial morbidity and mortality in adults and older children. • The correct recognition of HSE, and distinguishing it from other forms of encephalitis, brain abscess or mimicking disorders early in the course of evaluation facilitates treatment decisions when neurologic complications occur. • The combination of clinical characteristics, magnetic resonance imaging of the head, and polymerase chain reaction (PCR) analysis of cerebrospinal fluid for herpes simplex type 1 DNA is a sensitive and specific way of diagnosing HSE for proper treatment. • Early treatment is essential. HSE is treated with acyclovir 10 mg/kg every 8 hours intravenously for 21 days, unless the illness is mild, or if nephrotoxicity occurs. • Whether prolonged therapy with oral antiviral treatment after standard intravenous acyclovir offers any advantage from the standpoint of neurologic morbidity or mortality is unproven. • PCR-negative typical cases and PCR-positive atypical cases of HSE can occur and require treatment with acyclovir.

Original languageEnglish (US)
Pages (from-to)145-150
Number of pages6
JournalCurrent Treatment Options in Neurology
Volume7
Issue number2
DOIs
StatePublished - Jan 1 2005
Externally publishedYes

Fingerprint

Herpes Simplex Encephalitis
Acyclovir
Polymerase Chain Reaction
Nervous System
Therapeutics
Morbidity
Sick Leave
Brain Abscess
Herpes Simplex
Mortality
Encephalitis
Antiviral Agents
Cerebrospinal Fluid
Head
Magnetic Resonance Imaging
DNA

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Herpes simplex encephalitis in adults and older children. / Aksamit, Allen Jr.

In: Current Treatment Options in Neurology, Vol. 7, No. 2, 01.01.2005, p. 145-150.

Research output: Contribution to journalReview article

@article{430f09c69e8348209d52fd978898a068,
title = "Herpes simplex encephalitis in adults and older children",
abstract = "• Herpes simplex encephalitis (HSE) is a neurologically devastating illness associated with substantial morbidity and mortality in adults and older children. • The correct recognition of HSE, and distinguishing it from other forms of encephalitis, brain abscess or mimicking disorders early in the course of evaluation facilitates treatment decisions when neurologic complications occur. • The combination of clinical characteristics, magnetic resonance imaging of the head, and polymerase chain reaction (PCR) analysis of cerebrospinal fluid for herpes simplex type 1 DNA is a sensitive and specific way of diagnosing HSE for proper treatment. • Early treatment is essential. HSE is treated with acyclovir 10 mg/kg every 8 hours intravenously for 21 days, unless the illness is mild, or if nephrotoxicity occurs. • Whether prolonged therapy with oral antiviral treatment after standard intravenous acyclovir offers any advantage from the standpoint of neurologic morbidity or mortality is unproven. • PCR-negative typical cases and PCR-positive atypical cases of HSE can occur and require treatment with acyclovir.",
author = "Aksamit, {Allen Jr.}",
year = "2005",
month = "1",
day = "1",
doi = "10.1007/s11940-005-0023-1",
language = "English (US)",
volume = "7",
pages = "145--150",
journal = "Current Treatment Options in Neurology",
issn = "1092-8480",
publisher = "Current Science, Inc.",
number = "2",

}

TY - JOUR

T1 - Herpes simplex encephalitis in adults and older children

AU - Aksamit, Allen Jr.

PY - 2005/1/1

Y1 - 2005/1/1

N2 - • Herpes simplex encephalitis (HSE) is a neurologically devastating illness associated with substantial morbidity and mortality in adults and older children. • The correct recognition of HSE, and distinguishing it from other forms of encephalitis, brain abscess or mimicking disorders early in the course of evaluation facilitates treatment decisions when neurologic complications occur. • The combination of clinical characteristics, magnetic resonance imaging of the head, and polymerase chain reaction (PCR) analysis of cerebrospinal fluid for herpes simplex type 1 DNA is a sensitive and specific way of diagnosing HSE for proper treatment. • Early treatment is essential. HSE is treated with acyclovir 10 mg/kg every 8 hours intravenously for 21 days, unless the illness is mild, or if nephrotoxicity occurs. • Whether prolonged therapy with oral antiviral treatment after standard intravenous acyclovir offers any advantage from the standpoint of neurologic morbidity or mortality is unproven. • PCR-negative typical cases and PCR-positive atypical cases of HSE can occur and require treatment with acyclovir.

AB - • Herpes simplex encephalitis (HSE) is a neurologically devastating illness associated with substantial morbidity and mortality in adults and older children. • The correct recognition of HSE, and distinguishing it from other forms of encephalitis, brain abscess or mimicking disorders early in the course of evaluation facilitates treatment decisions when neurologic complications occur. • The combination of clinical characteristics, magnetic resonance imaging of the head, and polymerase chain reaction (PCR) analysis of cerebrospinal fluid for herpes simplex type 1 DNA is a sensitive and specific way of diagnosing HSE for proper treatment. • Early treatment is essential. HSE is treated with acyclovir 10 mg/kg every 8 hours intravenously for 21 days, unless the illness is mild, or if nephrotoxicity occurs. • Whether prolonged therapy with oral antiviral treatment after standard intravenous acyclovir offers any advantage from the standpoint of neurologic morbidity or mortality is unproven. • PCR-negative typical cases and PCR-positive atypical cases of HSE can occur and require treatment with acyclovir.

UR - http://www.scopus.com/inward/record.url?scp=14744287243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14744287243&partnerID=8YFLogxK

U2 - 10.1007/s11940-005-0023-1

DO - 10.1007/s11940-005-0023-1

M3 - Review article

AN - SCOPUS:14744287243

VL - 7

SP - 145

EP - 150

JO - Current Treatment Options in Neurology

JF - Current Treatment Options in Neurology

SN - 1092-8480

IS - 2

ER -